Canandaigua National Bank & Trust Co. Takes $3.86 Million Position in Pfizer Inc. $PFE

Canandaigua National Bank & Trust Co. purchased a new stake in Pfizer Inc. (NYSE:PFE) in the 2nd quarter, HoldingsChannel reports. The institutional investor purchased 160,394 shares of the biopharmaceutical company’s stock, valued at approximately $3,862,000.

A number of other large investors have also added to or reduced their stakes in the stock. Godfrey Financial Associates Inc. acquired a new position in Pfizer in the 4th quarter valued at $26,000. HFM Investment Advisors LLC grew its holdings in shares of Pfizer by 61.0% during the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 427 shares in the last quarter. Evolution Wealth Management Inc. increased its position in shares of Pfizer by 132.2% in the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 566 shares during the period. Abound Financial LLC acquired a new position in Pfizer in the fourth quarter valued at about $31,000. Finally, Darwin Wealth Management LLC acquired a new position in Pfizer in the second quarter valued at about $32,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer beat expectations with adjusted second-quarter EPS of $0.77 versus the $0.68 consensus and revenue of $15.03 billion versus $14.40 billion expected. Strong Eliquis demand and growth from oncology and other launched or acquired products helped offset weaker COVID sales. Pfizer beats quarterly profit estimates on strong demand for blood thinner Eliquis
• Positive Sentiment: The company raised the low end of its 2026 revenue outlook, increasing the range to $60.5 billion-$62.5 billion from $59.5 billion-$62.5 billion, or a $500 million increase at the midpoint. Pfizer maintained adjusted EPS guidance of $2.80-$3.00. Pfizer tops quarterly estimates, hikes low end of revenue guidance
• Positive Sentiment: Pfizer plans approximately $2.5 billion in additional cost reductions by 2029. Management also highlighted obesity-drug development, including a monthly GLP-1 candidate that could become a meaningful future growth driver if clinical data are favorable. Pfizer Says Monthly GLP-1 Candidate Could Rival Tirzepatide
• Neutral Sentiment: Pfizer’s recovery is becoming more diversified, but the company remains reliant on successful execution across oncology, Eliquis, acquired products, and its pipeline as older products mature. Pfizer Earnings Reveal New Engine Beyond Covid
• Negative Sentiment: COVID-19 product revenue continues to decline sharply, prompting analysts to reduce COVID forecasts. Pfizer also swung to a quarterly loss on reported results despite the adjusted earnings beat. PFE Q2 Earnings Top, 2026 Sales View Tweaked, COVID Forecast Cut
• Negative Sentiment: Healthcare stocks were broadly lower late in the session, adding sector pressure and helping explain why Pfizer’s strong results did not produce a sustained positive reaction. Sector Update: Healthcare Stocks Softer Late Afternoon

Analysts Set New Price Targets

A number of brokerages have issued reports on PFE. UBS Group reiterated a “neutral” rating and set a $27.00 price objective on shares of Pfizer in a research note on Wednesday, May 27th. Royal Bank Of Canada upgraded shares of Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 target price for the company in a research report on Tuesday, June 9th. BMO Capital Markets cut their price target on shares of Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a report on Monday, July 13th. Cantor Fitzgerald reiterated a “neutral” rating and set a $27.00 price target on shares of Pfizer in a research report on Monday, July 6th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Pfizer from $30.00 to $28.00 and set a “neutral” rating on the stock in a research note on Wednesday, July 8th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $28.50.

Pfizer Stock Performance

Pfizer stock opened at $25.35 on Wednesday. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67. The stock has a market cap of $144.50 billion, a PE ratio of 19.35 and a beta of 0.34. Pfizer Inc. has a 12-month low of $23.58 and a 12-month high of $28.75. The business’s 50-day moving average price is $25.02 and its two-hundred day moving average price is $26.16.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping analysts’ consensus estimates of $0.68 by $0.09. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The firm had revenue of $15.03 billion during the quarter, compared to analysts’ expectations of $14.40 billion. During the same quarter in the prior year, the business earned $0.78 earnings per share. The business’s revenue for the quarter was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, analysts expect that Pfizer Inc. will post 2.96 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 annualized dividend and a yield of 6.8%. Pfizer’s dividend payout ratio is presently 131.30%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.